{"id":3957,"date":"2026-06-28T06:20:00","date_gmt":"2026-06-28T12:20:00","guid":{"rendered":"https:\/\/portaltowellness.net\/research\/injectable-vs-oral-glp1-what-researchers-need-to-know\/"},"modified":"2026-10-09T09:33:49","modified_gmt":"2026-10-09T14:33:49","slug":"injectable-vs-oral-glp1-what-researchers-need-to-know","status":"publish","type":"ptw_resource","link":"https:\/\/portaltowellness.net\/es\/research\/injectable-vs-oral-glp1-what-researchers-need-to-know\/","title":{"rendered":"GLP-1 Inyectable vs. Oral: Lo que los Investigadores Necesitan Saber"},"content":{"rendered":"<style>.ptw-evidence-box{background:#fff;border:1px solid #e0d9c8;border-top:4px solid #8a7a4d;border-radius:10px;padding:22px 26px;margin:0 0 32px;}.ptw-evidence-box__header{font-size:13px;font-weight:700;letter-spacing:.08em;text-transform:uppercase;color:#1a2b4c;margin:0 0 16px;}.ptw-evidence-box__grid{display:grid;grid-template-columns:1fr 1fr;gap:12px 24px;margin-bottom:16px;}.ptw-evidence-box__label{display:block;font-size:11px;font-weight:700;letter-spacing:.06em;text-transform:uppercase;color:#8a7a4d;margin-bottom:3px;}.ptw-evidence-box__value{font-size:15px;color:#1a2b4c;font-weight:600;}.ptw-evidence-box__covers{margin:0 0 14px;padding-top:14px;border-top:1px solid #e0d9c8;}.ptw-evidence-box__covers p{margin:4px 0 0;font-size:15px;color:#333;}.ptw-evidence-box__refs{margin:0 0 14px;}.ptw-evidence-box__refs a{display:block;color:#1a2b4c;font-weight:600;text-decoration:underline;margin-top:2px;font-size:14px;}.ptw-evidence-box__note{margin:14px 0 0;padding-top:12px;border-top:1px solid #e0d9c8;font-size:12px;color:#777;font-style:italic;}@media(max-width:600px){.ptw-evidence-box__grid{grid-template-columns:1fr;}}<\/style>\n<div class=\"ptw-evidence-box\">\n<p class=\"ptw-evidence-box__header\">Evidence &amp; Research Status<\/p>\n<div class=\"ptw-evidence-box__grid\">\n<div><span class=\"ptw-evidence-box__label\">Evidence Level<\/span><span class=\"ptw-evidence-box__value\">Extensive Human Clinical Data<\/span><\/div>\n<div><span class=\"ptw-evidence-box__label\">FDA Status<\/span><span class=\"ptw-evidence-box__value\">Not FDA-approved for human use<\/span><\/div>\n<div><span class=\"ptw-evidence-box__label\">Regulatory Status<\/span><span class=\"ptw-evidence-box__value\">Research Use Only (RUO) \u2014 not for human consumption<\/span><\/div>\n<div><span class=\"ptw-evidence-box__label\">Last Updated<\/span><span class=\"ptw-evidence-box__value\">August 5, 2026<\/span><\/div>\n<\/div>\n<div class=\"ptw-evidence-box__covers\"><span class=\"ptw-evidence-box__label\">What This Article Covers<\/span><\/p>\n<p>The landscape of GLP-1 receptor agonist research shifted significantly in early 2026 when the FDA cleared oral semaglutide 25mg for chronic weight management \u2014 the first GLP-1 tablet approved in this\u2026<\/p>\n<\/div>\n<div class=\"ptw-evidence-box__refs\"><span class=\"ptw-evidence-box__label\">Primary References<\/span><a href=\"https:\/\/www.ajmc.com\/view\/fda-approves-oral-semaglutide-as-first-glp-1-pill-for-weight-loss\" rel=\"nofollow noopener\" target=\"_blank\">FDA Approves Oral Semaglutide \u2014 AJMC<\/a><a href=\"https:\/\/www.fiercepharma.com\/pharma\/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill\" rel=\"nofollow noopener\" target=\"_blank\">Source: Fierce Pharma Oral GLP-1 Tracker<\/a><\/div>\n<p class=\"ptw-evidence-box__note\">Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use.<\/p>\n<\/div>\n<p>The landscape of GLP-1 receptor agonist research shifted significantly in early 2026 when the FDA cleared oral semaglutide 25mg for chronic weight management \u2014 the first GLP-1 tablet approved in this category. For researchers studying GLP-1 pharmacology, this approval opens a new branch of inquiry: how does oral administration compare to subcutaneous injection across the dimensions that matter most in controlled research contexts?<\/p>\n<p>This article summarizes what the current literature reveals about each modality.<\/p>\n<hr \/>\n<style>\n.ptw-key-takeaways{background:#f6f3ec;border:1px solid #e0d9c8;border-left:4px solid #1a2b4c;border-radius:10px;padding:18px 22px;margin:24px 0;}\n.ptw-key-takeaways__label{margin:0 0 8px;font-size:11px;font-weight:700;letter-spacing:.08em;text-transform:uppercase;color:#8a7a4d;}\n.ptw-key-takeaways ul{margin:0;padding-left:20px;}\n.ptw-key-takeaways li{margin:4px 0;}\n<\/style>\n<div class=\"ptw-key-takeaways\">\n<p class=\"ptw-key-takeaways__label\">Key Takeaways<\/p>\n<ul>\n<li>Injectable and oral GLP-1 receptor agonists work through the same receptor but differ significantly in bioavailability.<\/li>\n<li>Oral delivery faces absorption challenges that injectable formulations avoid.<\/li>\n<li>Comparative trial data shows measurable differences in outcomes between the two delivery methods.<\/li>\n<li>Delivery method is a key research variable, not just a convenience factor.<\/li>\n<\/ul>\n<\/div>\n<div class=\"ptw-comparison-center\">\n<h2>Oral GLP-1 Comparison Center<\/h2>\n<p>Five GLP-1-pathway options are now in active use or late-stage development, spanning oral small molecules, oral peptides, and weekly injectables. The table below lines them up side by side on the attributes researchers ask about most; the fully sourced trial-by-trial breakdown follows in the sections below.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0;font-size:13px;\">\n<thead>\n<tr>\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;background:#f0f0f0;\">Attribute<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;background:#f0f0f0;\">Foundayo (orforglipron)<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;background:#f0f0f0;\">Oral Semaglutide 25mg<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;background:#f0f0f0;\">Injectable Semaglutide 2.4mg<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;background:#f0f0f0;\">Tirzepatide 15mg<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;background:#f0f0f0;\">Retatrutide 12mg<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;font-weight:600;\">Molecule type<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Non-peptide small molecule<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Peptide (SNAC-enhanced)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Peptide<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Peptide<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Peptide<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;font-weight:600;\">Receptor targets<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">GLP-1<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">GLP-1<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">GLP-1<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">GIP + GLP-1<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">GIP + GLP-1 + Glucagon<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;font-weight:600;\">Administration<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Once-daily oral<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Once-daily oral (fasted)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Once-weekly subcutaneous<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Once-weekly subcutaneous<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Once-weekly subcutaneous<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;font-weight:600;\">Food\/water restriction<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">None required<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Empty stomach, minimal water, wait period<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">None<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">None<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">None<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;font-weight:600;\">Refrigeration required<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Not required<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Not required<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Required<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Required<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Required<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;font-weight:600;\">Mean weight reduction (trial)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">11.2% (72wk, highest dose)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">16.6% (OASIS 4, 68wk)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">14.9% (STEP 1, 68wk)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">22.5% (SURMOUNT-1, 72wk)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">25.0% (TRIUMPH-1, 80wk)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;font-weight:600;\">FDA status<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Approved (US Apr 2026; UK-authorized Aug 2026)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Approved<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Approved<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Approved<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Investigational (BLA expected Q1 2027)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"font-size:13px;color:#666;\">Trial figures come from each program&#8217;s own pivotal or highest-dose data and are not head-to-head comparisons \u2014 different trials enroll different populations over different durations, so treat this table as a starting point, not a ranking. Full sourcing for each figure is in the Comparative Trial Data and Comparison Summary sections below.<\/p>\n<\/div>\n<h2>How GLP-1 Receptor Agonists Work<\/h2>\n<p>GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by L-cells in the intestinal tract in response to nutrient intake. GLP-1 receptor agonists are synthetic analogs that mimic this hormone, binding to GLP-1 receptors distributed throughout the body \u2014 including in pancreatic beta cells, the hypothalamus, the gastrointestinal tract, the heart, and the liver.<\/p>\n<p>In research subjects, GLP-1 receptor activation has been observed to influence appetite signaling, gastric emptying rate, insulin secretion (glucose-dependent), glucagon suppression, and energy homeostasis. The receptor&#8217;s broad distribution explains the compound class&#8217;s documented effects across metabolic, cardiovascular, hepatic, and neurological systems.<\/p>\n<hr \/>\n<h2>The Bioavailability Challenge of Oral Delivery<\/h2>\n<p>Peptides are notoriously difficult to deliver orally. The gastrointestinal environment degrades most peptide structures before systemic absorption can occur \u2014 proteolytic enzymes in the stomach and small intestine cleave peptide bonds, and the intestinal lining presents a poor absorption surface for large polar molecules.<\/p>\n<p>The 25mg oral semaglutide formulation uses SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), an absorption enhancer that transiently increases local pH near the gastric mucosa, protecting the peptide from enzymatic degradation and facilitating transcellular absorption. Oral bioavailability remains low (~1%) but sufficient for pharmacological effect at the doses studied. Strict administration conditions \u2014 taken fasted, with \u22644oz of water, 30 minutes before any food or other medications \u2014 are required to maintain absorption reliability.<\/p>\n<p>Injectable formulations (subcutaneous) bypass gastrointestinal barriers entirely, producing high, predictable bioavailability (approximately 89% for semaglutide 2.4mg).<\/p>\n<hr \/>\n<h2>Comparative Trial Data<\/h2>\n<h3>Oral Semaglutide 25mg \u2014 OASIS 4<\/h3>\n<p>The OASIS 4 Phase 3 trial evaluated once-daily oral semaglutide 25mg over 68 weeks:<\/p>\n<ul>\n<li><strong>Mean body weight reduction:<\/strong> 16.6% vs. 2.3% placebo<\/li>\n<li><strong>\u22655% body weight reduction:<\/strong> achieved by 76% of adherent participants<\/li>\n<li><strong>\u226520% body weight reduction:<\/strong> approximately 1 in 3 adherent participants vs. under 3% on placebo<\/li>\n<\/ul>\n<h3>Injectable Semaglutide 2.4mg \u2014 STEP 1<\/h3>\n<ul>\n<li><strong>Mean body weight reduction:<\/strong> 14.9% (68 weeks)<\/li>\n<li><strong>\u22655% body weight reduction:<\/strong> 86% of participants<\/li>\n<\/ul>\n<h3>Injectable Tirzepatide 15mg \u2014 SURMOUNT-1<\/h3>\n<ul>\n<li><strong>Mean body weight reduction:<\/strong> 22.5% (72 weeks)<\/li>\n<li><strong>\u226520% body weight reduction:<\/strong> 57% of participants<\/li>\n<\/ul>\n<h3>Retatrutide 12mg \u2014 TRIUMPH-1 (Phase 3, 2026)<\/h3>\n<ul>\n<li><strong>Mean body weight reduction:<\/strong> 25.0% at 12mg over 80 weeks<\/li>\n<li><strong>Severe obesity cohort:<\/strong> up to 30.3% \u2014 the largest pharmacological result on record<\/li>\n<li>FDA filing projected Q4 2026<\/li>\n<\/ul>\n<hr \/>\n<h2>Key Research Considerations: Oral vs. Injectable<\/h2>\n<h3>Pharmacokinetic Profile<\/h3>\n<ul>\n<li><strong>Injectable semaglutide (2.4mg, once-weekly):<\/strong> Tmax ~24 hours post-injection; half-life ~7 days; steady-state reached ~4\u20135 weeks. Consistent exposure between doses.<\/li>\n<li><strong>Oral semaglutide (25mg, once-daily):<\/strong> Tmax ~1 hour post-dose; shorter half-life requires daily dosing; plasma concentrations are more variable and highly sensitive to co-administration conditions.<\/li>\n<\/ul>\n<p>For research examining peak-concentration effects vs. sustained-exposure effects, this distinction is material.<\/p>\n<h3>Adherence and Administration Consistency<\/h3>\n<p>Injectable GLP-1 agonists require once-weekly subcutaneous self-administration, raising questions in research contexts around injection site variability, needle aversion, and administration technique. Once-daily oral dosing removes the injection variable but introduces strict fasting\/timing requirements that must be controlled for in any study design.<\/p>\n<h3>Receptor Targets and Mechanism Breadth<\/h3>\n<p>All semaglutide formulations share identical receptor selectivity \u2014 they are pure GLP-1 receptor agonists. The route of administration does not change the receptor biology. Tirzepatide and retatrutide extend the mechanism to GIP and glucagon receptors respectively, making them distinct research compounds rather than simply higher-efficacy versions of semaglutide.<\/p>\n<h3>Gastrointestinal Research<\/h3>\n<p>Because oral GLP-1 agonists transit through the GI tract before systemic absorption, researchers studying local GI effects (motility, secretion, mucosal inflammation) may find oral delivery a more relevant model for enteral GLP-1 receptor biology.<\/p>\n<hr \/>\n<h2>Comparison Summary<\/h2>\n<table>\n<thead>\n<tr>\n<th>Variable<\/th>\n<th>Oral Semaglutide 25mg<\/th>\n<th>Injectable Semaglutide 2.4mg<\/th>\n<th>Tirzepatide 15mg<\/th>\n<th>Retatrutide 12mg<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Receptor targets<\/td>\n<td>GLP-1<\/td>\n<td>GLP-1<\/td>\n<td>GIP + GLP-1<\/td>\n<td>GIP + GLP-1 + Glucagon<\/td>\n<\/tr>\n<tr>\n<td>Administration<\/td>\n<td>Once-daily oral (fasted)<\/td>\n<td>Once-weekly subcutaneous<\/td>\n<td>Once-weekly subcutaneous<\/td>\n<td>Once-weekly subcutaneous<\/td>\n<\/tr>\n<tr>\n<td>Bioavailability<\/td>\n<td>~1% (SNAC-enhanced)<\/td>\n<td>~89%<\/td>\n<td>~80%<\/td>\n<td>~75% (est.)<\/td>\n<\/tr>\n<tr>\n<td>Mean weight reduction<\/td>\n<td>16.6% (OASIS 4)<\/td>\n<td>14.9% (STEP 1)<\/td>\n<td>22.5% (SURMOUNT-1)<\/td>\n<td>25.0% (TRIUMPH-1)<\/td>\n<\/tr>\n<tr>\n<td>FDA status<\/td>\n<td>Approved<\/td>\n<td>Approved<\/td>\n<td>Approved<\/td>\n<td>Investigational (Q4 2026 filing)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr \/>\n<p><em>All compounds referenced in this article are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made. The administration routes and frequencies above describe how each FDA-approved or investigational pharmaceutical product is dosed per its own trial literature or label \u2014 not guidance for administering any product, including those sold by Portal to Wellness, which does not publish administration instructions for the research compounds in its catalog.<\/em><\/p>\n<p><strong>Sources:<\/strong><br \/>\n<a href=\"https:\/\/www.ajmc.com\/view\/fda-approves-oral-semaglutide-as-first-glp-1-pill-for-weight-loss\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">FDA Approves Oral Semaglutide \u2014 AJMC<\/a><br \/>\n<a href=\"https:\/\/www.ajmc.com\/view\/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">TRIUMPH-1 Phase 3 \u2014 Retatrutide AJMC<\/a><br \/>\nWilding JPH et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. <em>NEJM.<\/em> STEP 1.<br \/>\nJastreboff AM et al. (2022). Tirzepatide once weekly for the treatment of obesity. <em>NEJM.<\/em> SURMOUNT-1.<\/p>\n<style>\n.ptw-article-product-cta{display:flex;flex-wrap:wrap;align-items:center;justify-content:space-between;gap:16px;background:#f6f3ec;border:1px solid #e0d9c8;border-left:4px solid #1a2b4c;border-radius:10px;padding:20px 24px;margin:28px 0;}\n.ptw-article-product-cta__label{display:block;font-size:11px;font-weight:700;letter-spacing:.08em;text-transform:uppercase;color:#8a7a4d;margin-bottom:4px;}\n.ptw-article-product-cta__title{margin:0;font-size:18px;font-weight:700;color:#1a2b4c;}\n.ptw-article-product-cta__btn{display:inline-block;background:#1a2b4c;color:#fff !important;font-weight:600;text-decoration:none !important;padding:12px 22px;border-radius:6px;white-space:nowrap;}\n.ptw-article-product-cta__btn:hover{background:#2e4370;}\n@media (max-width:480px){.ptw-article-product-cta{flex-direction:column;align-items:flex-start;}.ptw-article-product-cta__btn{width:100%;text-align:center;}}\n<\/style>\n<p class=\"ptw-hub-backlink wp-block-paragraph\">\ud83d\udcda Part of our <a href=\"https:\/\/portaltowellness.net\/metabolic-research-kit\/\">GLP-1 &amp; Metabolic Research Guide<\/a> research guide.<\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f0ad4e;padding:16px 20px;margin:24px 0;border-radius:4px;\">\n<p style=\"margin:0 0 8px;font-weight:700;color:#8a6d3b;\">Update &#8212; August 3, 2026<\/p>\n<p style=\"margin:0;\">Both branded oral GLP-1 products referenced above are now on the market: Novo Nordisk&#8217;s oral Wegovy (oral semaglutide) launched January 5, 2026, and Eli Lilly&#8217;s Foundayo (orforglipron, a small-molecule non-peptide GLP-1 receptor agonist) followed with FDA approval April 1, 2026. Early commercial data shows a wide adoption gap &#8212; oral Wegovy topped 26,100 weekly prescriptions within its second week, while Foundayo was still near that same script level three months into its own launch, a pattern researchers attribute partly to slower PBM coverage (CVS did not cover Foundayo until June 1) rather than efficacy differences. Cross-trial reporting has also noted Foundayo carrying roughly 14&#215; higher odds of treatment discontinuation due to side effects than oral Wegovy, though this is a cross-trial comparison, not a head-to-head randomized trial, and should be treated as a hypothesis-generating signal rather than proof of comparative safety. <a href=\"https:\/\/www.fiercepharma.com\/pharma\/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill\" rel=\"nofollow noopener\" target=\"_blank\">Source: Fierce Pharma Oral GLP-1 Tracker<\/a>.<\/p>\n<\/div>\n<div style=\"background:#fff8e1;border-left:4px solid #f0ad4e;padding:16px 20px;margin:24px 0;border-radius:4px;\">\n<p style=\"margin:0 0 8px;font-weight:700;color:#8a6d3b;\">Update &#8212; August 6, 2026<\/p>\n<p style=\"margin:0;\">Lilly&#8217;s August 5, 2026 second-quarter results underscore that injectable demand has not been displaced by oral options: Mounjaro revenue rose 91% to roughly $9.9B and Zepbound rose about 44% to roughly $4.9B, while Foundayo (oral orforglipron) generated $98M in its first full quarter, a fraction of the injectable franchise. Lilly raised its full-year 2026 revenue guidance to $85 to $87B. Separately, Medicare&#8217;s new GLP-1 Bridge program (effective July 1, 2026) now covers both Foundayo and injectable Zepbound at a $50-per-month copay for eligible Part D patients, removing price as the main variable in the pill-vs-injection choice for that population. We could not independently verify a circulating claim that roughly 80% of patients entering the Medicare program chose injections over Foundayo; treat that specific figure as unconfirmed until Lilly or CMS publishes program-level utilization data. <a href=\"https:\/\/qz.com\/eli-lilly-earnings-q2-2026-revenue-forecast-weight-loss-080526\" rel=\"nofollow noopener\" target=\"_blank\">Source: Lilly Q2 2026 earnings coverage<\/a>.<\/p>\n<\/div>\n<div style=\"background:#f0f7f7;border-left:3px solid #2c7a7b;padding:14px 18px;margin:16px 0;border-radius:4px;\">\n<p style=\"margin:0;\"><strong>Update \u2014 August 11, 2026:<\/strong> The UK&#8217;s MHRA authorized orforglipron (Foundayo) on August 10, 2026, making the UK the first country in Europe to approve it, for both weight management (BMI \u226530, or BMI 27\u201330 with a weight-related comorbidity) and inadequately controlled type 2 diabetes. In the pivotal trial supporting this authorization, the highest Foundayo dose produced average weight loss of 11.2% at 72 weeks. Foundayo will launch in the UK later in August 2026 through private prescription only \u2014 it is not yet available via the NHS, and a NICE cost-effectiveness assessment will follow separately. Source: <a href=\"https:\/\/www.gov.uk\/government\/news\/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes\" target=\"_blank\" rel=\"noopener nofollow\">GOV.UK \/ MHRA<\/a>.<\/p>\n<\/div>\n<style>.ptw-related-content{background:#f6f3ec;border:1px solid #e0d9c8;border-left:4px solid #1a2b4c;border-radius:10px;padding:20px 24px;margin:32px 0;}.ptw-related-content h3{margin:0 0 14px;font-size:13px;font-weight:700;letter-spacing:.08em;text-transform:uppercase;color:#1a2b4c;}.ptw-related-content__group{margin:0 0 14px;}.ptw-related-content__group:last-child{margin-bottom:0;}.ptw-related-content__label{display:block;font-size:11px;font-weight:700;letter-spacing:.06em;text-transform:uppercase;color:#8a7a4d;margin-bottom:4px;}.ptw-related-content__group a{display:block;color:#1a2b4c;font-weight:600;text-decoration:underline;margin-top:2px;font-size:15px;}<\/style>\n<div class=\"ptw-related-content\">\n<h3>Continue Your Research<\/h3>\n<div class=\"ptw-related-content__group\"><span class=\"ptw-related-content__label\">Related Articles<\/span><a href=\"https:\/\/portaltowellness.net\/research\/glp1-biological-aging-epigenetic-research\/\">GLP-1 Receptor Agonists and Biological Aging: What the Research Shows<\/a><\/div>\n<div class=\"ptw-related-content__group\"><span class=\"ptw-related-content__label\">Related Products<\/span><a href=\"https:\/\/portaltowellness.net\/shop\/ptw-daily-essentials-kit\/\">PTW Daily Essentials Kit \u2014 Creatine, Electrolytes and Magnesium<\/a><a href=\"https:\/\/portaltowellness.net\/shop\/semaglutide-5mg-vial-research-use-only\/\">Semaglutide \u2013 5mg\/vial \u2014 Research Use Only<\/a><\/div>\n<div class=\"ptw-related-content__group\"><span class=\"ptw-related-content__label\">Related Research Guide<\/span><a href=\"https:\/\/portaltowellness.net\/metabolic-research-kit\/\">GLP-1 &amp; Metabolic Research Guide<\/a><\/div>\n<div class=\"ptw-related-content__group\"><span class=\"ptw-related-content__label\">Related Category<\/span><a href=\"https:\/\/portaltowellness.net\/metabolic-research-kit\/\">GLP-1 &amp; Metabolic Research Guide<\/a><\/div>\n<div class=\"ptw-related-content__group\"><span class=\"ptw-related-content__label\">Related FAQ<\/span><a href=\"https:\/\/portaltowellness.net\/faq\/\">General Research &amp; Ordering FAQ<\/a><\/div>\n<div class=\"ptw-related-content__group\"><span class=\"ptw-related-content__label\">More Research<\/span><a href=\"https:\/\/portaltowellness.net\/research\/\">Browse the full PTW Research Hub \u2192<\/a><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Evidence &amp; Research Status Evidence LevelExtensive Human Clinical Data FDA StatusNot FDA-approved for human use Regulatory StatusResearch Use Only (RUO) [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ptw_read_time":"","ptw_difficulty":"","ptw_featured_cta":"","ptw_cta_label":""},"ptw_resource_category":[526,528],"class_list":["post-3957","ptw_resource","type-ptw_resource","status-publish","hentry","ptw_resource_category-compound-deep-dives","ptw_resource_category-research-briefs"],"_links":{"self":[{"href":"https:\/\/portaltowellness.net\/es\/wp-json\/wp\/v2\/ptw_resource\/3957","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/portaltowellness.net\/es\/wp-json\/wp\/v2\/ptw_resource"}],"about":[{"href":"https:\/\/portaltowellness.net\/es\/wp-json\/wp\/v2\/types\/ptw_resource"}],"author":[{"embeddable":true,"href":"https:\/\/portaltowellness.net\/es\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":4,"href":"https:\/\/portaltowellness.net\/es\/wp-json\/wp\/v2\/ptw_resource\/3957\/revisions"}],"predecessor-version":[{"id":7820,"href":"https:\/\/portaltowellness.net\/es\/wp-json\/wp\/v2\/ptw_resource\/3957\/revisions\/7820"}],"wp:attachment":[{"href":"https:\/\/portaltowellness.net\/es\/wp-json\/wp\/v2\/media?parent=3957"}],"wp:term":[{"taxonomy":"ptw_resource_category","embeddable":true,"href":"https:\/\/portaltowellness.net\/es\/wp-json\/wp\/v2\/ptw_resource_category?post=3957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}